Verition Fund Management’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7,500
Closed -$506K – 2077
2026
Q2
$506K Buy
+7,500
New +$455K ﹤0.01% 1628
2024
Q4
– Sell
-22,036
Closed -$738K – 3228
2024
Q3
$738K Buy
+22,036
New +$753K ﹤0.01% 2087
2024
Q2
– Sell
-13,472
Closed -$303K – 2963
2024
Q1
$303K Buy
+13,472
New +$319K ﹤0.01% 2294
2023
Q3
– Sell
-24,380
Closed -$496K – 2327
2023
Q2
$496K Buy
+24,380
New +$494K 0.01% 1245

Other funds holding ANAB

Verition Fund Management's ANAB Position: Q3 2026 in Review

Verition Fund Management sold out of AnaptysBio (ANAB) in Q3 2026, closing a stake of 7,500 shares — an estimated $506K sold.

Verition Fund Management first reported a position in ANAB in Q2 2023 and held it in 4 quarters. The position peaked at $738K in Q3 2024. 229 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

  • Verition Fund Management reported no remaining AnaptysBio position as of Q3 2026 after selling out during the quarter.
  • Verition Fund Management sold 7,500 AnaptysBio shares in Q3 2026, an estimated $506K.
  • Verition Fund Management first reported a position in AnaptysBio in Q2 2023 and held it in 4 quarters.
  • Verition Fund Management's AnaptysBio position peaked at $738K in Q3 2024.
  • 229 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.